Pub Date : 2008-06-28DOI: 10.1111/j.1523-5394.2001.91004.pp.x
Margot E. Kurtz ph d, J. C. Kurtz ph d, Manfred Stommel ph d, Charles W. Given ph d, Barbara Given ph d, rn, faan
Purpose: The purpose of this study was to help identify factors to assess which elderly patients are likely to experience problems with physical and psychological functioning in association with cancer or its treatment.
description of Study: A study was undertaken with a sample of 420 patients with cancer who were between the ages of 65 and 98 years and had received an incident diagnosis of breast, colon, lung, or prostate cancer. An analysis of covariance technique was used to determine how cancer site, treatment type, stage of disease, gender, age, comorbidity, symptom severity, and prediagnosis levels of physical functioning were related to physical functioning deficit, and how all of these in turn influenced patient depressive symptomatology.
Results: Prediagnosis physical functioning, symptom severity, and days since surgery were significant predictors of physical functioning deficit. Patients who had been treated only with surgery experienced greater physical functioning deficits than did patients who had received both surgery and adjuvant therapy. This apparent anomaly was partly explained by the time interval from surgery to interview. Higher levels of symptom severity, lower levels of prior physical functioning, and greater physical functioning deficits all predicted higher levels of depressive symptomatology.
clinical Implications: In the care of elderly patients with cancer, it is important for healthcare providers to consider the prediagnosis levels of physical functioning of patients with cancer to understand and anticipate the physical and psychological consequences of cancer and its treatment. Equally important is the proper management of patient symptoms in maximizing both the physical and psychological quality of life.
{"title":"Physical Functioning and Depression Among Older Persons with Cancer","authors":"Margot E. Kurtz \u0000 ph\u0000\t\t\t\t\t\td, J. C. Kurtz \u0000 ph\u0000\t\t\t\t\t\td, Manfred Stommel \u0000 ph\u0000\t\t\t\t\t\td, Charles W. Given \u0000 ph\u0000\t\t\t\t\t\td, Barbara Given \u0000 ph\u0000\t\t\t\t\t\td, rn, \u0000\t\t\t\t\t\tfaan","doi":"10.1111/j.1523-5394.2001.91004.pp.x","DOIUrl":"10.1111/j.1523-5394.2001.91004.pp.x","url":null,"abstract":"<p><b><span>Purpose:</span></b> The purpose of this study was to help identify factors to assess which elderly patients are likely to experience problems with physical and psychological functioning in association with cancer or its treatment.</p><p><b><span>description of Study:</span></b> A study was undertaken with a sample of 420 patients with cancer who were between the ages of 65 and 98 years and had received an incident diagnosis of breast, colon, lung, or prostate cancer. An analysis of covariance technique was used to determine how cancer site, treatment type, stage of disease, gender, age, comorbidity, symptom severity, and prediagnosis levels of physical functioning were related to physical functioning deficit, and how all of these in turn influenced patient depressive symptomatology.</p><p><b><span>Results:</span></b> Prediagnosis physical functioning, symptom severity, and days since surgery were significant predictors of physical functioning deficit. Patients who had been treated only with surgery experienced greater physical functioning deficits than did patients who had received both surgery and adjuvant therapy. This apparent anomaly was partly explained by the time interval from surgery to interview. Higher levels of symptom severity, lower levels of prior physical functioning, and greater physical functioning deficits all predicted higher levels of depressive symptomatology.</p><p><b><span>clinical Implications:</span></b> In the care of elderly patients with cancer, it is important for healthcare providers to consider the prediagnosis levels of physical functioning of patients with cancer to understand and anticipate the physical and psychological consequences of cancer and its treatment. Equally important is the proper management of patient symptoms in maximizing both the physical and psychological quality of life.</p>","PeriodicalId":79323,"journal":{"name":"Cancer practice","volume":"9 1","pages":"11-18"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1523-5394.2001.91004.pp.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63186812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-28DOI: 10.1111/j.1523-5394.2001.96009.pp.x
Georgi Pirtskhalaishvili md, phd, Ronald L. Hrebinko md , Joel B. Nelson md
Purpose: The purpose of this report is to discuss the current treatment options available to the patient with prostate cancer in all stages of the disease.
Overview: With the exception of skin cancer, prostate cancer is the most common cancer in men in the United States. Most patients in the current era will present with organ-confined disease, amenable to curative treatment. Treatment for organ-confined disease includes watchful waiting, radical prostatectomy, radiation therapy, and cryosurgery in selective cases. Hormone therapy is the cornerstone of treatment of patients with advanced prostate cancer. There is no curative treatment for hormone-refractory prostate cancer.
Clinical implications: The availability of several therapeutic options for localized prostate cancer warrants careful consideration when planning treatment with curative intent. Patients need to be active participants in decision making, and they must be aware of the benefits and possible complications of the different types of treatment. Patients with advanced prostate cancer need to be aware that hormone treatment will provide temporization and palliation in the majority of cases. Hormone-resistant prostate cancer is refractory to most forms of conventional and experimental therapy.
{"title":"The Treatment of Prostate Cancer.","authors":"Georgi Pirtskhalaishvili \u0000 md, phd, Ronald L. Hrebinko \u0000 md\u0000 , Joel B. Nelson \u0000 md","doi":"10.1111/j.1523-5394.2001.96009.pp.x","DOIUrl":"10.1111/j.1523-5394.2001.96009.pp.x","url":null,"abstract":"<p><b><span>Purpose:</span></b> The purpose of this report is to discuss the current treatment options available to the patient with prostate cancer in all stages of the disease.</p><p><b><span>Overview:</span></b> With the exception of skin cancer, prostate cancer is the most common cancer in men in the United States. Most patients in the current era will present with organ-confined disease, amenable to curative treatment. Treatment for organ-confined disease includes watchful waiting, radical prostatectomy, radiation therapy, and cryosurgery in selective cases. Hormone therapy is the cornerstone of treatment of patients with advanced prostate cancer. There is no curative treatment for hormone-refractory prostate cancer.</p><p><b><span>Clinical implications:</span></b> The availability of several therapeutic options for localized prostate cancer warrants careful consideration when planning treatment with curative intent. Patients need to be active participants in decision making, and they must be aware of the benefits and possible complications of the different types of treatment. Patients with advanced prostate cancer need to be aware that hormone treatment will provide temporization and palliation in the majority of cases. Hormone-resistant prostate cancer is refractory to most forms of conventional and experimental therapy.</p>","PeriodicalId":79323,"journal":{"name":"Cancer practice","volume":"9 6","pages":"295-306"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1523-5394.2001.96009.pp.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63187058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-28DOI: 10.1111/j.1523-5394.2000.86001.pp.x
Martha Crosier Wood mba , Catherine Tomeo Ryan mph
{"title":"Resources on Colorectal Cancer for Patients","authors":"Martha Crosier Wood \u0000 mba\u0000 , Catherine Tomeo Ryan \u0000 mph","doi":"10.1111/j.1523-5394.2000.86001.pp.x","DOIUrl":"https://doi.org/10.1111/j.1523-5394.2000.86001.pp.x","url":null,"abstract":"","PeriodicalId":79323,"journal":{"name":"Cancer practice","volume":"8 6","pages":"308-310"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1523-5394.2000.86001.pp.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91881623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-28DOI: 10.1111/j.1523-5394.2001.95003.pp.x
Kavita K. Parmar bsc(pharm), pharmd, Reginald S. King pharmd, bcop
{"title":"Imatinib Mesylate:","authors":"Kavita K. Parmar \u0000 bsc(pharm), pharmd, Reginald S. King \u0000 pharmd, bcop","doi":"10.1111/j.1523-5394.2001.95003.pp.x","DOIUrl":"https://doi.org/10.1111/j.1523-5394.2001.95003.pp.x","url":null,"abstract":"","PeriodicalId":79323,"journal":{"name":"Cancer practice","volume":"9 5","pages":"263-265"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1523-5394.2001.95003.pp.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71984470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-28DOI: 10.1111/j.1523-5394.2001.96002.pp.x
Erin Medoff APRN, AOCN, Arlene D. Houldin PhD, CS, RN, Carrie Tompkins Stricker MSN, RN, CRNP, AOCN, Stephen Anderson PhD, Lisa Chertkov MD
{"title":"Communication Challenges in a Young Man with Hodgkin's Disease","authors":"Erin Medoff APRN, AOCN, Arlene D. Houldin PhD, CS, RN, Carrie Tompkins Stricker MSN, RN, CRNP, AOCN, Stephen Anderson PhD, Lisa Chertkov MD","doi":"10.1111/j.1523-5394.2001.96002.pp.x","DOIUrl":"10.1111/j.1523-5394.2001.96002.pp.x","url":null,"abstract":"","PeriodicalId":79323,"journal":{"name":"Cancer practice","volume":"9 6","pages":"272-276"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1523-5394.2001.96002.pp.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63186923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-28DOI: 10.1111/j.1523-5394.2001.91010.pp.x
Sallie K. Young BSc(pharm), pharm d
{"title":"New Advances in the Management of Cutaneous T-Cell Lymphoma","authors":"Sallie K. Young BSc(pharm), \u0000\t\t\t\t\t\tpharm\u0000\t\t\t\t\t\td","doi":"10.1111/j.1523-5394.2001.91010.pp.x","DOIUrl":"https://doi.org/10.1111/j.1523-5394.2001.91010.pp.x","url":null,"abstract":"","PeriodicalId":79323,"journal":{"name":"Cancer practice","volume":"9 1","pages":"52-54"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1523-5394.2001.91010.pp.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71984695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-28DOI: 10.1111/j.1523-5394.2001.91008.pp.x
James S. Gordon md
{"title":"Creating Comprehensive Cancer Care","authors":"James S. Gordon \u0000 md","doi":"10.1111/j.1523-5394.2001.91008.pp.x","DOIUrl":"https://doi.org/10.1111/j.1523-5394.2001.91008.pp.x","url":null,"abstract":"","PeriodicalId":79323,"journal":{"name":"Cancer practice","volume":"9 1","pages":"47-49"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1523-5394.2001.91008.pp.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71979772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号